The EPS miss relative to consensus, combined with flat adjusted gross margin and rising SG&A, tempers the positive revenue beat. Watch for progress on Brazilian virginiamycin regulatory approvals, which could unlock upside to maintained guidance, and monitor the Chicago Heights facility closure for cost savings.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $35.40entry
- T+1 · 11d ago −6.89%α −7.21% · $32.96
- T+5 · 5d ago +0.17%α −3.12% · $35.46
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Phibro Animal Health reported Q1 FY2027 net sales of $386.8M (+6% YoY) and GAAP diluted EPS of $0.72 (+11% YoY), slightly below the consensus EPS estimate of $0.78. Adjusted diluted EPS was $0.79, also below the $0.79 consensus. The company maintained its FY2027 guidance for net sales of $1.55B-$1.60B and adjusted EBITDA of $258M-$268M. The annual shareholder meeting ratified all director nominees and PwC as auditor.
Key Financial Metrics
Key Facts
- Net sales of $386.8M for Q1 ended Sep 30, 2026, up 6% YoY from $363.9M
- GAAP diluted EPS of $0.72, up 11% YoY from $0.65
- Adjusted diluted EPS of $0.79, up 8% YoY from $0.73
- Consensus EPS estimate was $0.78; actual GAAP EPS of $0.72 was a miss of 7.7%
- Revenue of $386.8M vs consensus of $383.0M, a beat of 1.0%
- FY2027 guidance maintained: net sales $1.55B-$1.60B, adjusted EBITDA $258M-$268M
- Animal Health segment sales grew 3% to $293.0M, with MFAs up 6% but virginiamycin sales in Brazil down $5.2M
- Mineral Nutrition sales up 17% to $73.6M; Performance Products up 16% to $20.2M
- Gross margin improved 30 bps to 33.2%; adjusted gross margin flat at 34.0%
- SG&A increased 15% to $78.9M, including $0.6M in restructuring charges for Chicago Heights closure
- Operating income declined 3% to $49.6M due to higher SG&A
- Free cash flow of $21.7M for trailing twelve months; gross leverage 2.9x
- Annual meeting: all three Class I director nominees elected; PwC ratified as auditor with 99.4% support
Financial Impact
Q1 revenue beat consensus by $3.8M (1.0%), but GAAP EPS missed by $0.06 (7.7%); adjusted EPS of $0.79 matched consensus. Guidance maintained, no change to outlook.
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Animal Health | $293.0M | +3.4% |
| Mineral Nutrition | $73.6M | +16.8% |
| Performance Products | $20.2M | +16.1% |
Risk Factors
- GAAP EPS of $0.72 missed consensus of $0.78 by 7.7%, which may pressure the stock near-term
- Animal Health adjusted EBITDA declined 1% YoY despite 3% sales growth, as SG&A rose faster
- Virginiamycin sales in Brazil remain suspended due to regulatory developments, with no assumed recovery in guidance
- SG&A grew 15% YoY, outpacing revenue growth of 6%, compressing operating margins
- Restructuring charges for Chicago Heights closure add near-term costs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-122727 |
| Document: pahc-20261103x8k.htm | 0001104659-26-122727 |
| Document: 0001104659-26-122727-index-headers.html | 0001104659-26-122727 |
| Document: 0001104659-26-122727-index.html | 0001104659-26-122727 |
| Document: 0001104659-26-122727.txt | 0001104659-26-122727 |
| 8-K Data (Synthetic) | 0001104659-26-122727 |
Track record
9 reports on PAHC
1 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +37.96% at T+20 after the Apr 27, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 4, 202612d ago 8-K Neutral 4/10 Viewing Entry $35.40 to $35.46 Now $35.02 −1.07% ▲ +0.17% −3.12% vs SPY
- Nov 3, 202613d ago 8-K Neutral 2/10 Entry $39.43 to $35.15 Now $35.02 −11.18% ▼ −10.85% −9.94% vs SPY
- Oct 19, 202628d ago SC 13G/A Bearish 5/10 Entry $38.80 to $38.38 Now $35.02 +9.74% ▲ +1.08% +1.16% vs SPY
- Jul 28, 202615w ago 8-K Neutral 2/10 Entry $36.95 to $36.01 Now $35.02 −5.22% ▼ −2.54% −8.07% vs SPY
- Jun 26, 202620w ago 8-K Neutral 2/10 Entry $31.81 to $34.13 Now $35.02 +10.09% ▲ +7.29% +5.91% vs SPY
- May 6, 202627w ago 8-K Bullish 6/10 Entry $43.16 to $35.26 Now $35.02 −18.86% ▼ −18.30% −19.81% vs SPY
- May 5, 202627w ago 8-K Neutral 2/10 Entry $58.50 to $36.58 Now $35.02 −40.14% ▼ −37.47% −38.60% vs SPY
- Apr 30, 202628w ago 8-K Neutral 4/10 Entry $54.66 to $39.83 Now $35.02 −35.93% ▼ −27.13% −29.47% vs SPY
- Apr 27, 202629w ago 8-K Bearish 5/10 Entry $54.29 to $54.68 Now $35.02 +35.49% ▼ −0.72% +0.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers